Répertoire de l'Université Alfonso X el Sabio

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial

Afficher la notice abrégée

APA

Romero, Atocha & Jantus Lewintre, Eloisa & García Pelaez, Beatriz & Royuela, Ana & Insa, Amelia & Cruz, Patricia & Collazo, Ana & Perez Altozano, Javier & Juan Vidal, Oscar & Diz, Pilar & Cobo, Manuel & Hernandez, Berta & Vazquez Estevez, Sergio & Benítez, Gretel & Guirado, Maria & Majem, Margarita & Bernabe, Reyes & Ortega, Ana Laura & Blasco, Ana & Bosch Barrera, Joaquim & Jurado, Jose M. & García Gonzalez, Jorge & Viteri, Santiago & Garcia Giron, Carlos & Massutí, Bartomeu & López Martín, Ana & Rodriguez Festa, Alejandro & Calabuig Fariñas, Silvia & Molina Vila, Miguel Angel & Provencio, Mariano (2021 ) .Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.

ISO 690

Romero, Atocha & Jantus Lewintre, Eloisa & García Pelaez, Beatriz & Royuela, Ana & Insa, Amelia & Cruz, Patricia & Collazo, Ana & Perez Altozano, Javier & Juan Vidal, Oscar & Diz, Pilar & Cobo, Manuel & Hernandez, Berta & Vazquez Estevez, Sergio & Benítez, Gretel & Guirado, Maria & Majem, Margarita & Bernabe, Reyes & Ortega, Ana Laura & Blasco, Ana & Bosch Barrera, Joaquim & Jurado, Jose M. & García Gonzalez, Jorge & Viteri, Santiago & Garcia Giron, Carlos & Massutí, Bartomeu & López Martín, Ana & Rodriguez Festa, Alejandro & Calabuig Fariñas, Silvia & Molina Vila, Miguel Angel & Provencio, Mariano. 2021 .Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.

https://hdl.handle.net/20.500.12080/39710
dc.contributor.author Romero, Atocha
dc.contributor.author Jantus Lewintre, Eloisa
dc.contributor.author García Pelaez, Beatriz
dc.contributor.author Royuela, Ana
dc.contributor.author Insa, Amelia
dc.contributor.author Cruz, Patricia
dc.contributor.author Collazo, Ana
dc.contributor.author Perez Altozano, Javier
dc.contributor.author Juan Vidal, Oscar
dc.contributor.author Diz, Pilar
dc.contributor.author Cobo, Manuel
dc.contributor.author Hernandez, Berta
dc.contributor.author Vazquez Estevez, Sergio
dc.contributor.author Benítez, Gretel
dc.contributor.author Guirado, Maria
dc.contributor.author Majem, Margarita
dc.contributor.author Bernabe, Reyes
dc.contributor.author Ortega, Ana Laura
dc.contributor.author Blasco, Ana
dc.contributor.author Bosch Barrera, Joaquim
dc.contributor.author Jurado, Jose M.
dc.contributor.author García Gonzalez, Jorge
dc.contributor.author Viteri, Santiago
dc.contributor.author Garcia Giron, Carlos
dc.contributor.author Massutí, Bartomeu
dc.contributor.author López Martín, Ana
dc.contributor.author Rodriguez Festa, Alejandro
dc.contributor.author Calabuig Fariñas, Silvia
dc.contributor.author Molina Vila, Miguel Angel
dc.contributor.author Provencio, Mariano
dc.date.accessioned 2024-02-12T11:04:39Z
dc.date.available 2024-02-12T11:04:39Z
dc.date.created 2021
dc.date.issued 2021
dc.identifier.uri https://hdl.handle.net/20.500.12080/39710
dc.description.abstract Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. Herein, seven methodologies including two next-generation sequencing (NGS)-based methods, three high-sensitivity PCR-based plat forms, and two FDA-approved methods were compared using 72 plasma samples, from EGFR-mutant non-small-cell lung cancer (NSCLC) patients progressing on a first-line tyrosine kinase inhibitor (TKI). NGS platforms as well as high-sensitivity PCR-based methodologies showed excellent agreement for EGFR-sensitizing mutations (K = 0.80¿0.89) and substantial agreement for T790M testing (K = 0.77 and 0.68, respectively). Mutant allele frequencies (MAFs) obtained by different quantitative methods showed an excellent reproducibility (intraclass correlation coefficients 0.86¿ 0.98). Among other technical factors, discordant calls mostly occurred at mutant allele frequencies (MAFs) ¿ 0.5%. Agreement significantly improved when discarding samples with MAF ¿ 0.5%. EGFR mutations were detected at significantly lower MAFs in patients with brain metas tases, suggesting that these patients risk for a false-positive result. Our results support the use of liquid biopsies for noninvasive EGFR testing and highlight the need to systematically report MAFs. es_ES
dc.format application/pdf es_ES
dc.language eng es_ES
dc.rights CC-BY es_ES
dc.rights.uri http://creativecommons.org/licenses/by/4.0/deed.es es_ES
dc.title Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.rights.accessrights info:eu-repo/semantics/openAccess es_ES
dc.identifier.location N/A es_ES


Fichier(s) constituant ce document

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

CC-BY Excepté là où spécifié autrement, la license de ce document est décrite en tant que CC-BY

Chercher dans le dépôt


Parcourir

Mon compte

Social Media